医学
脑膜中动脉
心理干预
栓塞
开颅术
血肿
优势比
神经外科
逻辑回归
外科
风险因素
队列
内科学
精神科
作者
Angelica M. Fuentes,Syed Khalid,Ankit I. Mehta
出处
期刊:Neurosurgery
[Oxford University Press]
日期:2022-09-21
卷期号:92 (1): 144-149
被引量:3
标识
DOI:10.1227/neu.0000000000002151
摘要
Middle meningeal artery (MMA) embolization has recently emerged as an effective technique to treat subdural hematomas (SDHs). Studies to date have been limited, largely, to single-center studies with limited follow-up and have not assessed subsequent surgical interventions and factors associated with these interventions.To evaluate rates of retreatment for SDH after MMA embolization and patient-specific factors that may be important predictors for these interventions.Using an all-payer claims database, Mariner, patients who underwent MMA embolization between January 2010 and October 2020 after the diagnosis of SDH were identified. Rates of post-MMA embolization surgical interventions, including craniotomy and burr hole drainage, were accessed within 5 years following. Patient-specific contributors to the rates of these interventions were studied using Gaussian logistic regression models.A total of 322 patients were included. Of this cohort, 55 (17.1%) required subsequent intervention within 5 years, with 36 (11.2%) receiving burr hole evacuation and 19 (5.9%) receiving craniotomy. Factor Xa inhibitor use was independently associated with subsequent interventions after MMA embolization procedures (odds ratio: 1.20 [95% CI: 1.02-1.40]). Of the other patient factors evaluated, including age, sex, comorbidity status, and use of vitamin K antagonists, antiplatelets, and factor Xa inhibitors, none were found to be significantly associated with future interventions.Although previous literature has shown MMA embolization to be safe and successful in preventing recurrent SDH, patients undergoing this procedure still carry a risk of future interventions. Patients taking factor Xa inhibitors are at especially high risk of subsequent intervention after MMA embolization.
科研通智能强力驱动
Strongly Powered by AbleSci AI